Protocol ID

Trial Title

CDR0000512836; UVACC-MEL-47; NCI-7190; NCT00397982

A Phase II Study of CCI-779 in Combination With Bevacizumab in Stage III or IV Melanoma

BO18255; NCT01041404

A Randomized, Open Llabel Study of the Effect of First Line Herceptin in Combination With a Fluoropyrimidine and Cisplatin Versus Chemotherapy Alone on Overall Survival in Patients With HEr2-positive Advanced Gastric Cance

CDR0000593048; LUMC-LU200027; ABRAXIS-LU200027; NCT00654836

A Phase II Study of Carboplatin, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Avastin as the First Line Therapy in Metastatic Breast Cancer.

CDR0000634119; ECOG-E2905; NCT00843882

Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia

SCRI REFMAL 122; NCT00613145

A Phase I Pharmacokinetic and Safety Study of Sorafenib + Capecitabine in Advanced Solid Tumors

CDR0000066076; RTOG-9704; E-R9704; SWOG-R9704; NCT00003216

A Phase III Study of Pre and Post Chemoradiation with 5-FU vs. Pre and Post Chemoradiation with Gemcitabine for Postoperative Adjuvant Treatment of Resected Pancreatic Adenocarcinoma

AVF4200g; BO20904; NCT00548548

Double Blind, Randomised, Multicenter, Phase III Study of Bevacizumab in Combination With Capecitabine and Cisplatin Versus Placebo in Combination With Capecitabine and Cisplatin, As First Line Therapy in Patients With Advanced Gastric Cancer

CDR0000455114; GOG-0218; NCT00262847

A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab Followed By Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Suboptimal Advanced Stage Epithelial Ovarian, Primary Peritoneal Cancer, or Fallopian Tube Cancer

NOV002-C301; NCT00347412

Randomized, Open Label, Phase III Trial of NOV-002 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-small Cell Lung Cancer (NSCLC)